Eightco (NASDAQ: ORBS) Releases Monthly Chairman’s Message

Eightco holds over 10% of the current WLD supply in circulation Introducing Infinity by ORBS, which brings authentication to the enterprise and commercial; with inaugural partners including Coinbase, Kraken and more Infinity by ORBS addresses proof-of-human authentication at scale to wide range of industries including, Finance, Advertising, Gaming, Government The Company is supported by a […]

FIH Clinical Trial Planning for Radiopharmaceuticals: From IND to Patient Dosing, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into how to design and execute a first-in-human trial for a radiopharmaceutical agent. The featured speakers will discuss regulatory considerations across the US, EU and other global regions. The speakers will also share best practices for site readiness, radiation compliance and isotope logistics. Attendees will learn about operational strategies

Biomarker Testing: Pushing the Limits of Ultrasensitivity, Upcoming Webinar Hosted by Xtalks

In this free webinar by KCAS Bio, learn about the growing need for ultrasensitive bioanalytical platforms and kits, especially in disciplines like neuroscience, where analytes are often present at very low concentrations in peripheral circulation. Attendees will gain insight into NULISA™/Argo™ HT capabilities and how the platform pushes the limits of biomarker sensitivity and applies

Managing Placebo Risk in Dermatology Trials, Upcoming Webinar Hosted by Xtalks

In this free webinar, gain insight into the scientific factors that lead to higher placebo response in dermatology studies. The featured speakers will share practical operational strategies to minimize placebo risk through design, site training and patient management. Attendees will learn how new levels of regulatory transparency from EMA and FDA affect oversight and accountability.

Chubb Appoints Bill Hazelton Chief Operating Officer, North America Field Operations

Chubb today announced that Bill Hazelton has been appointed to Chief Operating Officer for North America Field Operations, effective December 1, 2025. https://mma.prnewswire.com/media/2824930/Chubb_Bill_Hazelton.jpg In this role, Bill will oversee the delivery of Chubb's full portfolio of personal and commercial insurance products and services to agent and broker distribution partners through 48 branch offices across North

ATI President and CEO Kimberly A. Fields Elected Board Chair

Robert S. Wetherbee to retire as Executive Chair and Board member ATI Inc. (NYSE: ATI) announced that the Board of Directors has elected Kimberly A. Fields to become Board Chair of ATI, in addition to her roles as Chief Executive Officer and President. This appointment becomes effective May 14, 2026, at ATI's Annual Meeting of

Crisis24 Global Risk Forecast 2026: Future Ready, Now

Annual report equips organizations to seize opportunities in a world that is faster, more connected and harder to predict Crisis24, a global, AI-enhanced provider in integrated risk management, intelligence-led security and medical operations, personal protection, medical concierge and crisis consulting, today announced the rollout of the Crisis24 Global Risk Forecast 2026. This report provides an

P2P GROUP RECEIVES CONDITIONAL ACCEPTANCE FOR NAME CHANGE TO INTURAI VENTURES

(CSE: PPB / FSE: 3QG / OTCQB: PPBGF)investor@p2p-group.com Highlights — Rebrand to reflect core focus on Inturai's spatial intelligence platform — New ticker symbol “URAI” aligns with its defence, AI and sensing technologies development — Business model advancement aligned with platformcommercialisation and military-sector expansion P2P Group Ltd. (the “Company”) (CSE: PPB) (OTC: PPBGF) (FSE: 3QG)is

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tablets The new unexpected PK profile allows for a once daily therapeutic regimen thus potentially improving long term adherence and expected to significantly reduce the drug

Scroll to Top